Takeda to acquire Oral Allosteric TYK2 Inhibitor NDI-034858 from Nimbus Therapeutics

Japan: Takeda has announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment...

Related Keywords

Christophe Weber ,Cleary Gottlieb Steen Hamilton ,Research Development At Takeda ,Evercore Group ,Andy Plump ,Costa Saroukos ,Antitrust Improvements Act ,Cleary Gottlieb Steen ,Takeda ,Takeda News ,Acquisition ,Ndi 034858 ,Nimbus Therapeutics ,Psoriasis ,Tak 279 , ,